title: Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
authors: Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY 10965, USA.|Kadmon Pharmaceuticals, New York, NY 10016, USA.
authors: Anthony M
authors: AM
authors: Barsotti
authors: Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY 10965, USA.
authors: Michael
authors: M
authors: Ryskin
authors: Oncology Research Unit, Pfizer Worldwide Research & Development, Pearl River, NY 10965, USA.
authors: Robert A
authors: RA
authors: Rollins
mesh_terms: D000071221:Enhancer of Zeste Homolog 2 Protein; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006657:Histones / Q000378:metabolism; D006801:Humans; D008239:Lysine / Q000378:metabolism; D008745:Methylation / Q000187:drug effects; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D063151:Polycomb Repressive Complex 2 / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D006657:Histones; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D008239:Lysine
keywords: EZH2; epigenetic reprogramming; epigenetic therapy; gain-of-function mutations; histone methylation; melanoma; polycomb